The DOI matches its Crossref record.
Su1930 – Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly Selective, Cannabinoid Receptor 2 Agonist in a Phase 2A Study in Chronic Abdominal Pain Associated with Crohn’s Disease
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The cannabinoid type-2 receptor agonist, olorinab, has been tested in patients with quiescent Crohn's disease, and led to reductions in abdominal pain and improved bowel movements 293”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [293]
In the citing paper
“In an openlabel trial in patients with quiescent Crohn's disease, it reduced abdominal pain and improved bowel movements”
From Irritable bowel syndrome (2020) · cites this paper as [148]
Citations
Cites
Still being checked.
Cited by
Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31548-8 · Cited by 818
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease
Sinopoulou, V., Gordon, M. A., Akobeng, A. K., Gasparetto, M., Sammaan, M., Vasiliou, J., & Dovey, T. M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013531.pub2 · Cited by 69
Role of Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease
Gotfried, J., Naftali, T., & Schey, R. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.087 · Cited by 49
Review article: current and future treatment approaches for pain in IBS
Paine, P. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16550 · Cited by 46
Metadata
- Authors
- Yacyshyn, B., Ginsberg, D. C., Gilder, K., Walsh, B., English, B., Turner, S. A., Klassen, P., Hanauer, S. B., Barish, C. F., & Higgins, P. D.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 156
- Issue
- 6
- Pages
- S-665
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2943880659
- Cited by
- 17
- References
- 0
- Citations by year
- 2023: 2 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 3
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Gastroenterology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- cannabinoid receptor 2 agonist, chronic abdominal pain, Crohn's disease, drug safety, drug efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Su1930 – Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly Selective, Cannabinoid Receptor 2 Agonist in a Phase 2A Study in Chronic Abdominal Pain Associated with Crohn’s Disease. https://app.cochat.ai/papers/10.1016/s0016-5085(19)38567-1
- The paper
- Yacyshyn, B., Ginsberg, D. C., Gilder, K., Walsh, B., English, B., Turner, S. A., Klassen, P., Hanauer, S. B., Barish, C. F., & Higgins, P. D. (2019). Su1930 – Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly Selective, Cannabinoid Receptor 2 Agonist in a Phase 2A Study in Chronic Abdominal Pain Associated with Crohn’s Disease. Gastroenterology. https://doi.org/10.1016/s0016-5085(19)38567-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.